Abstract
The development of biological disease-modifying anti-rheumatic drugs (bDMARDs) has been a breakthrough in rheumatology. In this article, the general principles of bDMARD-treatment will be described based on 2 patient cases. Most bDMARDs inhibit cytokines: signaling molecules that transmit messages within the immune system. Because specific cytokines play a dominant role in different rheumatic diseases, this determines which agent is used for which indication. Another group of bDMARDs targets B cells, and is increasingly used for the treatment of SLE and vasculitis. Finally, we will briefly discuss side effects and precautions to provide an optimal overview for understanding rheumatologic bDMARD-treatment.
| Translated title of the contribution | Biologicals in rheumatology: an overview of mechanisms of action and applications |
|---|---|
| Original language | Dutch |
| Article number | D8051 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 168 |
| Publication status | Published - 5 Mar 2024 |
Keywords
- Humans
- Rheumatology
- Antirheumatic Agents/adverse effects
- Cytokines
- Vasculitis